Global Companion Diagnostics Market Report 2018: Research Focus on Advancing New Diagnostics and Therapeutics

Dublin, Nov. 21, 2018 (GLOBE NEWSWIRE) -- The "Companion Diagnostics: Biomarker Platforms Enabling Precision Medicine" report has been added to ResearchAndMarkets.com's offering.

Both predictive and prognostic biomarkers constitutes an central element in each and every targeted oncology drug discovery and development program. Breakthrough technologies allowing leveraging biomarkers for oncology are paving the way of personalized medicine and precision oncology. Indeed, oncology biomarkers provide the clinical community with the opportunity to offer individualized therapies and health programs.

Furthermore, oncology biomarkers enable to get critical information about the mechanism of action of a drug or target, to profoundly study carcinogenesis process, and to match patient characteristics specifically to the most appropriate treatment.

Key Topics Covered:

1.0 Executive Summary
1.1 Companion Diagnostics: The Bigger Picture
1.2 Research Focus: Advancing New Diagnostics and Therapeutics
1.3 Research Scope: Unveiling Novel Diagnostics Pathways
1.4 Analysis Framework: Core Values
1.5 Research Methodology: Five Steps toward Success

2.0 Technology Snapshot and Trends
2.1 Key Elements of Analysis: The Companion Diagnostics' Concept
2.2 Brief Overview of Companion Diagnostics
2.3 Effectiveness and Performance Validation for CDx
2.4 Overall Landscape of Cancer Companion Diagnostics
2.5 Precision Oncology Accelerated Pathway
2.6 Biomarker Stratification for Companion Diagnostics
2.7 Emerging Opportunities for Companion Diagnostics

3.0 Technology Status Review and Assessment
3.1 Technology Synergy Reshaping Value Chain
3.2 Product Development and Commercialization
3.3 Technology and Business Landscape: Accelerators
3.4 Technology and Business Landscape: Challenges
3.5 New Approaches Driving Companion Diagnostics Solutions

4.0 Impact of Companion Diagnostics on the Pharmaceutical Industry
4.1 Market Dynamics and Opportunities
4.2 Market Potential: Technology Focus Segmentation
4.3 Market Potential: Therapeutic Area and Regional Segmentation
4.4 Impact of Companion Diagnostics on Therapeutic Areas
4.5 Prominent Pharmaceutical Market Leaders

5.0 Business Strategy Models
5.1 The Role of Stakeholders in Business Strategy
5.2 Technology Transfer Assessment and Perceptions
5.3 Disruptive Companion Diagnostics Solutions
5.4 Business Model Hybridization
5.5 Overall Environmental Impact Factors
5.6 Future Perspective for Companion Diagnostics

6.0 Funding and Investment Landscape
6.1 Key Funding and Investment Opportunities
6.2 Funding and Investment Models and Adoption
6.3 Funding Long Shots, Securitization, and Credit
6.4 Strategic Collaborations

7.0 Performance Benchmarking
7.1 Multicriteria Approach for Benchmarking
7.2 Strategic Portfolio Assessment
7.3 Level 1 Criteria: Innovation Development
7.4 Level 1 Criteria: Financial Performance
7.5 Level 1 Criteria: Market Evolution
7.6 Level 2 Criteria: Key Actions for Success
7.7 Analytic Performance Results
7.8 Multicriteria Final Assessment
7.9 Strategic Imperatives: Critical Success Factors

8.0 Key Industry Influencers

For more information about this report visit https://www.researchandmarkets.com/research/f47zjk/global_companion?w=12

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

                    CONTACT: ResearchAndMarkets.com
                             Laura Wood, Senior Press Manager
                             press@researchandmarkets.com
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900
                    Related Topics: Genomics, Biomarkers